Products / Onchology y Oncohematology

Zutrab

Bevacizumab 100 mg/4 ml - 400 mg/16 ml

Bevacizumab is indicated for the treatment of colon cancer, lung cancer and ovarian cancer.

Therapeutic Action

Antineoplastic

Presentations

1 vial

Zutrab Bevacizumab 100 mg/4 ml - 400 mg/16 ml de Laboratorios Richmond
Download Prospect

Legal Notice

Products which continue to have a valid patent protection at present are manufactured in line with the current laws of the Argentine Republic. Please, take into account that our products will only be shipped to countries where the substance and its use are not protected by patents.

Laboratorios Richmond S.A.C.I.F. Argentina © All rights reserved Terms of use